Filing Details
- Accession Number:
- 0001209191-14-053326
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-19 16:03:28
- Reporting Period:
- 2014-08-15
- Filing Date:
- 2014-08-19
- Accepted Time:
- 2014-08-19 16:03:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1488613 | Foundation Medicine Inc. | FMI | Services-Medical Laboratories (8071) | 271316416 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1402017 | J Michael Pellini | 150 Second Street C/O Foundation Medicine, Inc. Cambridge MA 02141 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-08-15 | 4,500 | $25.61 | 505,500 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-08-18 | 8,000 | $25.10 | 497,500 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2014.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.60 to $25.73, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.92 to $25.35, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.